BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9240732)

  • 21. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women.
    Tsai KS; Hsu SH; Yang RS; Cheng WC; Chieng PU
    Calcif Tissue Int; 1999 May; 64(5):384-8. PubMed ID: 10203414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
    J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.
    Välimäki MJ; Tiihonen M; Laitinen K; Tähtelä R; Kärkkäinen M; Lamberg-Allardt C; Mäkelä P; Tunninen R
    J Bone Miner Res; 1994 May; 9(5):631-7. PubMed ID: 8053391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V; Briot K; Roux C; Roy C; Seksik P; Charachon A; Bouhnik Y; Coffin B; Allez M; Lamarque D; Chaussade S
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
    Meunier PJ; Confavreux E; Tupinon I; Hardouin C; Delmas PD; Balena R
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2784-91. PubMed ID: 9284696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
    Khan SA; Kanis JA; Vasikaran S; Kline WF; Matuszewski BK; McCloskey EV; Beneton MN; Gertz BJ; Sciberras DG; Holland SD; Orgee J; Coombes GM; Rogers SR; Porras AG
    J Bone Miner Res; 1997 Oct; 12(10):1700-7. PubMed ID: 9333131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T; McGuigan L; Barbagallo S; Bryant C
    Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation.
    Henderson K; Eisman J; Keogh A; MacDonald P; Glanville A; Spratt P; Sambrook P
    J Bone Miner Res; 2001 Mar; 16(3):565-71. PubMed ID: 11277275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy.
    Pouilles JM; Tremollieres F; Roux C; Sebert JL; Alexandre C; Goldberg D; Treves R; Khalifa P; Duntze P; Horlait S; Delmas P; Kuntz D
    Osteoporos Int; 1997; 7(3):213-8. PubMed ID: 9205633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
    Gürlek A; Bayraktar M; Gedik O
    Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males.
    Gram J; Junker P; Nielsen HK; Bollerslev J
    Bone; 1996 Jun; 18(6):539-44. PubMed ID: 8805994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of early postmenopausal bone loss with cyclical etidronate.
    Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R
    J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss.
    Rymer J; Robinson J; Fogelman I
    Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
    Schlosser K; Scigalla P
    Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
    Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.
    Ward RL; Morgan G; Dalley D; Kelly PJ
    Bone Miner; 1993 Aug; 22(2):87-94. PubMed ID: 8251768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25-dihydroxyvitamin D (Calcitriol) for four years.
    Sairanen S; Kärkkäinen M; Tähtelä R; Laitinen K; Mäkelä P; Lamberg-Allardt C; Välimäki MJ
    Calcif Tissue Int; 2000 Aug; 67(2):122-7. PubMed ID: 10920216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.